Literature DB >> 31275806

Capnocytophaga sputigena: An unusual cause of community-acquired pneumonia.

Laurie Gosse1, Sophie Amrane2, Morgane Mailhe2, Grégory Dubourg2, Jean-Christophe Lagier1,2.   

Abstract

Capnocytophaga sputigena is an unusual cause of community-acquired pneumonia. A 22-year-old woman presented an amoxicillin-resistant pneumonia. Sputum examination detected C. sputigena from 3 specimens with a significant bacterial load. The strain produced beta lactamase. Evolution was favorable after introduction of amoxicillin-clavulanate acid. Physicians might be aware of the presence of this unusual bacterium in cases of community-acquired pneumonia.

Entities:  

Keywords:  Capnocytophaga sputigena; Community-acquired pneumonia

Year:  2019        PMID: 31275806      PMCID: PMC6587014          DOI: 10.1016/j.idcr.2019.e00572

Source DB:  PubMed          Journal:  IDCases        ISSN: 2214-2509


Introduction

Capnocytophaga sputigena is a capnophilic gram-negative fusiform bacillus belonging to the family Flavobacteriaceae. This bacterium was first described in 1979 and belongs to the normal flora of the subgingival throat [1]. There is no national or international epidemiological surveillance of this bacterium. As for pulmonary infections, they still seem very little described. Here, we report a case of pneumonia with C. sputigena.

Clinical case

In July 2018, a 22-year-old woman with a severe obesity, for which she underwent sleeve gastrectomy, was hospitalized in our infectious diseases unit, in the IHU Méditeranée Infection, Marseille, France. For 2 weeks she had rhinorrhoea associated with fever without improvement under symptomatic treatment. Subsequently, symptoms worsened with dyspnoea, coughing, fever and purulent sputum. Amoxicillin was introduced as acute community pneumonia was suspected. After 8 days of antibiotic therapy, the symptoms persisted and led the patient to consult again in the emergency department. Clinically, she presented cough with sputum associated with crackles at the two pulmonary bases. The rest of the clinical exam was normal. Chest radiograph showed a focal infection of the left lower lung lobe associated with diffuse interstitial syndrome (Fig. 1). Standard blood test analysis found moderate inflammatory syndrome with CRP at 45 mg/L without hyperleucocytosis or any other abnormality. On the microbiological level, Legionella pneumophila and Streptococcus pneumoniae urinary antigens were negative. We decided to empirically change antibiotic therapy for levofloxacin in this atypical pneumonia resistant to amoxicillin.
Fig. 1

Chest radiograph highlighting a pneumonia.

Chest radiograph highlighting a pneumonia. Three semi-quantitative cultures of sputum specimen were performed, for which C. sputigena was found predominant. The isolate identified by MALDI-TOF MS grew at 107CFU/mL in all specimens. Antibiotic susceptibility testing was performed according to the EUCAST recommendations using Haemophilus spp. breakpoints and evinced a resistance to amoxicillin and a susceptibility to amoxicillin-clavulanic acid. According to these results, amoxicillin-clavulanic acid was introduced. In parallel, this atypical case of pneumonia due to C. sputigena was documented. The patient entirely recovered after 7 days of treatment.

Discussion

C. sputigena is rarely implicated in pulmonary infection, most of the described cases related its implication in bacteraemia or amniotic infections [2]. To the best of our knowledge, only five other cases of C. sputigena pulmonary infection have been described (Table 1). Infection can occur in immunocompetent hosts, and Lo et al. reported the case of a bilateral pneumonia with pleural effusion in an 84-year-old man. C. sputigena was detected on blood cultures [3]. Li et al. presented a case of a 68-year-old immunocompetent man with persistent pleural effusion for whom C. sputigena was detected on a pleural drain [4]. C. sputigena has also been involved in a respiratory infection following care; a 67-year-old old man, who underwent fibroscopy for exploration of a suspicious pulmonary mass, presented fever 7 days after the procedure, and a lung abscess was diagnosed. C. sputigena was isolated from the latter and histological analysis detected a lung cancer [5]. Furthermore, C. sputigena was involved in a lung abscess in a 39-year-old immunocompromised host suffering from a neuroendocrine tumor. Interestingly, the biochemical testing identified the isolate as C. ochracea or C. sputigena [6]. Finally, the pediatric population can be affected as Atmani et al. related the case of a 12-year-old girl with pleural effusion involving C. sputigena [7].
Table 1

Cases report of C. sputigena pulmonary infections previously reported.

Cases reportSexAgePast medical historyImmuno-suppressionClinical presentationPositive culture onDetection byTreatmentDeath
Atmani S, et al. Arch Pediatr.2008F12NoneNoFebrile pleural effusionPleural fluid16S RNA sequencingAmoxicillinRifampicinNo
Li A, et al.J Clin Microbiol. 2013M64Hypertensive intracranial hemorrhage vascular dementia, parotid pleomorphe adenomaNoPleural empyema with unfavorable evolution (treated since one month)Pleural fluidMALDI-TOF MS(Codetection ofP. aeruginosa)Amoxicillin CiprofloxacinNo
Lo SH1, et al.J Microbiol Immunol Infect.2017M84Stroke, diapletic seizure, high blood pressure, type 2 diabetic mellitus, benign prostatic hypertrophy, gastric cancerGastric cancerDiabetic mellitusRelapsing bilateral pneumonia with pleural effusionBlood cultureMALDI-TOF MS16S RNA sequencingPiperacillin tazobactamNo
Migiyama Y, et al.J Infect Chemother.2018M67Prostatic cancerLung cancerLung abscess seven days after fibroscopy for pulmonary mass explorationLung abscess fluidMALDI-TOF MSMeropenemNo
Our caseF22Severe obesity, sleeve gastrectomyNoPneumoniaSputumMALDI-TOF MSAmoxicillinClavulanic acidNo
Cases report of C. sputigena pulmonary infections previously reported. Our case is the first in which C. sputigena is recovered from a sputum specimen. Sputum might be a difficult sample for interpretation and diagnosis of this infection, as the bacterium is a commensal of the oral flora. However, in our case, C. sputigena was detected on three samples and with a significant bacterial load. Moreover, clinical response was correlated with antibiotic susceptibility as the introduction of a beta-lactamase inhibitor improved the clinical course. The bacterium was identified by MALDI-TOF mass spectrometry, which is the technique that has been used in recent case reports [[3], [4], [5]]. Evolution was unfavourable following amoxicillin treatment. Capnocytophaga is now often resistant to beta-lactam because of its beta-lactamase production. Adjunction of a beta-lactam inhibitor is recommended when a treatment against Capnocytophaga is initiated [8]. As an example, in our lab, since 2013, among the 51 samples found positive for C. sputigena, we found that 55% were sensitive to amoxicillin, while 100% were sensitive to amoxicillin-clavulanic acid.

Conclusion

We present here the first documented case of pneumonia caused by C. sputigena after sputum examination, and the second case described in France. The repeated culture of this bacterium from the sputum samples of the same patient should alert microbiologists and infectious disease clinicians, as this bacterium can, in rare occasion, cause pneumonia.

Conflicts of interest

We have no conflict of interest.

Funding

We have no funding source.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Author contribution

LG, and SA: data collection, data analysis and writing; MM and GD: data analysis and reviewing the manuscript; JCL: study design; writing.

Ethical approval

Not applicable.
  1 in total

1.  The Brief Case: Capnocytophaga sputigena Bacteremia in a 94-Year-Old Male with Type 2 Diabetes Mellitus, Pancytopenia, and Bronchopneumonia.

Authors:  Benjamin M Liu; Christopher P Carlisle; Mark A Fisher; Salika M Shakir
Journal:  J Clin Microbiol       Date:  2021-06-18       Impact factor: 5.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.